| Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages |
|
Dae Ho Lee |
|
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea |
| 종양면역치료: 중세 암흑시대에서 르네상스시대로 |
|
이대호 |
|
울산대학교 의과대학 서울아산병원 종양내과 |
Correspondence:
Dae Ho Lee, Tel: +82-2-3010-3214, Fax: +82-2-3010-6961, Email: leedaeho@amc.seoul.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
| Abstract |
|
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley’s toxin, induced tumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to its lack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understanding of the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancer immunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapy and other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here, I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines, and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonal antibodies. |
| Key Words:
Cancer; Immunotherapy; Anti-immune checkpoint antibody |
| 주제어:
종양; 면역치료; 항면역검문항체 |
|
PDF Links
Full text via DOI
Download Citation
